NCT06362226View on ClinicalTrials.gov

Optimizing Ocular Outcomes: A Dual-armed Study for Periorbital Burn Management

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

January 31, 2027

Conditions
Periorbital Burns
Interventions
DRUG

Steroid/Antibiotic (Maxitrol)

Group one subjects receive topical maxitrol ophthalmic ointment twice daily for two weeks

DRUG

5-FU/Kenalog

Group two undergoes treatment with a subcutaneous injection of a 5-fluorouracil (5-FU) and Kenalog (triamcinolone) combination (80/20 ratio, 0.3-0.5 mL per session) administered in four sessions, spaced two weeks apart, starting within 48 hours of hospital presentation

All Listed Sponsors
lead

Virginia Commonwealth University

OTHER